Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Total Non-current Liabilities
All obligations due after more than one year.
Ascendis Pharma A/SNASDAQ: ASND
Total Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total non-current liabilities rises 10.3% from a year ago
Total non-current liabilities stood at €377.65M at the end of Q3 FY2026, up 10.3% from a year earlier and down 1.8% from the prior quarter. Over 3 fiscal years it compounded at +53.4% a year.
Context
- Total non-current liabilities amounted to 15.6% of total assets at the end of Q3 FY2026, down 14.1 pp from a year earlier.
- Total non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +10.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
EUR · from the balance sheet
- Latest · FY2025
- 395.83M EUR
- Year-over-year change
- +4.9%
- 4-year CAGR
- +40.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 395.83M | +4.9% |
| FY2024 | 2024-12-31 | 377.34M | +60.7% |
| FY2023 | 2023-12-31 | 234.78M | +114.2% |
| FY2022 | 2022-12-31 | 109.61M | +8.6% |
| FY2021 | 2021-12-31 | 100.93M | — |
Total Non-current Liabilities vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +10.3% is the 6th highest of 11, against a peer median of +12.3%.
- Total non-current liabilities amounts to 15.6% of total assets for ASND, versus a peer median of 13.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $3.71T USD | +488024.6% | -14.2% | 32.1% | |
| Mar 2026 | $1.2B USD | +38.1% | +9.4% | 92.6% | |
| Jun 2026 | $906.33M USD | -1.3% | -8.5% | 43.1% | |
| Sep 2026 | $764.1M USD | +22.4% | +72.7% | 13.6% | |
| Sep 2026 | €377.65M EUR | +10.3% | +53.4% | 15.6% | |
| Mar 2026 | $260.41M USD | +1.9% | +4.9% | 66.4% | |
| Jun 2026 | $212M USD | +2.3% | -37.3% | 2.9% | |
SEPNSepterna, Inc. | Sep 2026 | $86.61M USD | -39.3% | +19.4% | 14.0% |
| Jun 2026 | $29.12M USD | +37.0% | +35.8% | 3.3% | |
| Mar 2026 | $7.59M USD | -37.4% | -41.2% | 1.7% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $2.5M USD | +426.1% | -82.8% | 0.5% |
| Peer median (excluding ASND) | — | +12.3% | -1.8% | 13.8% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 446.27M | 444.77M | 392.16M | 559.54M | 615.78M |
| Short-term Investments | 235.8M | 290.69M | 7.28M | 0 | 0 |
| Net Receivables | 2.2M | 11.91M | 35.87M | 166.28M | 157.63M |
| Inventory | 75.41M | 130.67M | 208.93M | 295.61M | 301.4M |
| Other Current Assets | 20.99M | 13.72M | 19.9M | 11.16M | 0 |
| Total Current Assets | 805.89M | 923.47M | 702.72M | 1.06B | 1.11B |
| Property, Plant & Equipment (Net) | 126.05M | 129.1M | 110.63M | 98.71M | 146.42M |
| Goodwill | 3.5M | 3.5M | 3.5M | 3.5M | 3.49M |
| Intangible Assets | 1.78M | 1.33M | 924K | 533K | 214.91K |
| Long-term Investments | 145.91M | 30.42M | 5.69M | 13.58M | 43.38M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.81M | 1.92M | 2.13M | 2.32M | 0 |
| Total Non-current Assets | 279.04M | 166.27M | 122.87M | 118.63M | 193.5M |
| Total Assets | 1.08B | 1.09B | 825.59M | 1.18B | 1.3B |
| Account Payables | 59.42M | 101.03M | 94.57M | 96.39M | 90.62M |
| Short-term Debt | 7M | 412.98M | 421.27M | 491.54M | 486.32M |
| Tax Payables | 198K | 5.49M | 2.3M | 1.22M | 0 |
| Deferred Revenue | 2.6M | 0 | 1.18M | 936K | 4.94M |
| Other Current Liabilities | 24.15M | 183.49M | 203.02M | 317.78M | 480.63M |
| Total Current Liabilities | 100.36M | 716.78M | 736.51M | 907.86M | 1.07B |
| Long-term Debt | 97.97M | 95.4M | 223M | 365.08M | 385.09M |
| Deferred Tax Liabilities | 0 | 0 | 5.83M | 7.26M | 9.62M |
| Deferred Revenue (Non-current) | 2.96M | 14.21M | 5.95M | 5M | 1.12M |
| Other Non-current Liabilities | (97.97M) | (95.4M) | (84.62M) | 0 | 0 |
| Total Non-current Liabilities | 100.93M | 109.61M | 234.78M | 377.34M | 395.83M |
| Total Liabilities | 201.29M | 826.39M | 971.28M | 1.29B | 1.46B |
| Common Stock | 7.65M | 7.68M | 7.75M | 8.15M | 8.32M |
| Retained Earnings | (1.24B) | (1.86B) | (2.28B) | (2.56B) | (2.7B) |
| Accumulated OCI | 3.78M | 3.45M | 721K | 1.78M | (1.75M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 883.64M | 263.35M | (145.7M) | (105.71M) | (162.75M) |
| Total Debt | 209.92M | 617.57M | 743.06M | 856.62M | 871.41M |
| Net Debt | (236.35M) | 172.8M | 350.89M | 297.07M | 255.64M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.